EGFR Amplification Modulation to Overcome Cancer Therapy Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The mechanisms underlying EGFR amplification in cancer cells are poorly understood, leading to drug resistance and heterogeneity, which complicates the development of effective therapeutic strategies for EGFR-amplified cancers.
Innovation Solution
The use of inhibitors such as EZH2, KDM5, and KDM5A inhibitors to modulate EGFR amplification levels, combined with EGFR inhibitors like gefitinib or lapatinib, to sensitize tumor cells to EGFR-targeted therapies by reducing tumor heterogeneity and proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If EGFR amplification occurs in cancer cells, then tumor growth is promoted, but sensitivity to EGFR-targeted therapies is reduced
Solution Approach 1:
The patent applies parameter changes by modulating the amplification level of EGFR through epigenetic regulators. By changing the copy number parameter of EGFR from amplified to reduced levels, the patent simultaneously addresses tumor growth control and therapy sensitivity improvement, resolving the contradiction between these two features
Solution Approach 2:
The patent employs preliminary action by using epigenetic modifiers to reduce EGFR amplification before administering EGFR-targeted therapies. This preparatory step sensitizes tumor cells to subsequent EGFR inhibitor treatment, preventing the development of resistance and improving therapeutic outcomes
2Reliability
If epigenetic modifiers are used to reduce EGFR amplification, then therapy sensitivity is improved, but treatment complexity increases
Solution Approach 1:
The patent utilizes epigenetic modifiers that perform multiple functions: they reduce EGFR amplification, decrease tumor heterogeneity, and sensitize cells to EGFR inhibitors simultaneously. This multi-functionality approach improves therapy sensitivity without proportionally increasing treatment complexity, as a single class of compounds addresses multiple therapeutic challenges
Data Source
Figure 1A~1D
Figure 1E~1H
Figure 1I~1M
AI summary
Compositions and methods for regulating EGFR amplification in cancer are disclosed.